Supplement Library
FULL SUPPLEMENT: Tildrakizumab In Everyday Dermatology: Clinical Insights From Challenging Psoriasis Cases
October 2026 | Volume 25 | Issue 10 | Department | 435800s1 | Copyright © October 2026
Tildrakizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds the p19 subunit of interleukin-23 (IL-23), a key cytokine in the pathogenesis of psoriasis. In the pivo...
Read MoreINDIVIDUAL ARTICLE: Tildrakizumab for Real-World Psoriasis Care: Clinical Lessons From Medically Complex and Underserved Patient Populations
October 2026 | Volume 25 | Issue 10 | Supplement Individual Articles | 435801s4 | Copyright © October 2026
Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin-23, has demonstrated durable efficacy and a favorable long-term safety profile in moderate-to-severe plaque p...
Read MoreFULL SUPPLEMENT: Ammonium Lactate for Xerotic Skin Conditions: Biomimetic Effects and Clinical Relevance
October 2026 | Volume 25 | Issue 10 | Department | 946300s1 | Copyright © October 2026
Xerosis is a common and clinically significant dermatologic concern, affecting patients across a broad spectrum of conditions, including atopic dermatitis, psoriasis, ichthyosis, and age- or environme...
Read MoreINDIVIDUAL ARTICLE: Ammonium Lactate in Clinical Practice: Optimizing Treatment of Xerotic and Hyperkeratotic Skin Conditions
October 2026 | Volume 25 | Issue 10 | Supplement Individual Articles | 946302s4 | Copyright © October 2026
Ammonium lactate is a well-established, time-tested dermatologic therapy with a substantial body of clinical evidence supporting its use inxerotic and hyperkeratotic skin conditions....
Read MoreINDIVIDUAL ARTICLE: Beyond Moisturization: Ammonium Lactate as a Biomimetic Regulator of Skin Barrier Function
October 2026 | Volume 25 | Issue 10 | Supplement Individual Articles | 946301s10 | Copyright © October 2026
The stratum corneum (SC) is essential for maintaining skin barrier integrity through coordinated interactions between corneocytes, intercellular lipids, and natural moisturizing factors (NMFs). L...
Read MoreFULL SUPPLEMENT: The Hidden Burden of Topical Corticosteroids: Integrating Literature, Prescribing Information, and Real-World Evidence
November 2026 | Volume 25 | Issue 11 | Department | 104190s1 | Copyright © November 2026
INDIVIDUAL ARTICLE: Cutaneous and Systemic Adverse Events Associated With Topical Corticosteroid Use: A Targeted Literature Review
November 2026 | Volume 25 | Issue 11 | Supplement Individual Articles | 10419s4 | Copyright © November 2026
Background: Topical corticosteroids (TCS) have been used to treat chronic inflammatory skin conditions since initial approval in 1950, which was followed by reports of cutaneous an...
Read MoreINDIVIDUAL ARTICLE: Topical Corticosteroid Approved Labeling in the US: A Modern Inter- and Intra-Product Analysis
November 2026 | Volume 25 | Issue 11 | Supplement Individual Articles | 10424s11 | Copyright © November 2026
Background: A wide variety of prescription-strength topical corticosteroids (TCS) have been commercially available for many decades. Product labels often vary, reflecting inconsist...
Read MoreINDIVIDUAL ARTICLE: Real-World Study of Topical Corticosteroid-Associated Adverse Events in the FDA Adverse Event Reporting System
November 2026 | Volume 25 | Issue 11 | Supplement Individual Articles | 10425s21 | Copyright © November 2026
Background: Corticosteroids (CS) and topical CS (TCS) are widely used, yet the real-world burden and reporting patterns of associated adverse events (AEs) remain incompletely chara...
Read MoreFULL SUPPLEMENT: The Role of IL 31 Inhibition in Atopic Dermatitis
September 2026 | Volume 25 | Issue 9 | Department | 154710s1 | Copyright © September 2026
Atopic dermatitis and prurigo nodularis represent the two most burdensome pruritic inflammatory skin diseases encountered in clinical dermatology. While distinct in morphology, chronicity, and epidemi...
Read MoreINDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab
September 2026 | Volume 25 | Issue 9 | Supplement Individual Articles | 015471s2 | Copyright © September 2026
Interleukin-31 (IL-31) is a central mediator in atopic dermatitis (AD) and prurigo nodularis (PN), functioning both as the principal pruritogeniccytokine, driving itch through direct...
Read MoreFULL SUPPLEMENT: Real-World Split-Face Case Series of a Phyto Polydeoxyribonucleotide (PDRN) Serum in Integrative Skincare
September 2026 | Volume 25 | Issue 9 | Department | 15490s1 | Copyright © September 2026
Inflammation and photodamage are largely considered the leading contributors to premature skin aging as they lead to decreased collagen content in the skin. Collagen, the most abundant protein in the ...
Read MoreINDIVIDUAL ARTICLE: Real-World Cases Using Phyto Polydeoxyribonucleotide (PDRN) Serum
September 2026 | Volume 25 | Issue 9 | Supplement Individual Articles | 15491s2 | Copyright © September 2026
Background: Integrative skincare refers to a clinician-directed regimen that combines aesthetic procedures with appropriate post-procedure skincare. The novel phyto polydeoxyribo...
Read MoreFULL SUPPLEMENT: Research on Generalized Pustular Psoriasis
August 2026 | Volume 25 | Issue 8 | Department | 63120 | Copyright © August 2026
Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening disease of immunologic dysfunction. The pathophysiology of the disease was not well understood until recently. As a...
Read MoreINDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management
August 2026 | Volume 25 | Issue 8 | Supplement Individual Articles | 63121 | Copyright © August 2026
Observations: Emerging epidemiologic, clinical, and real-world data establish GPP as a distinct disease entity associated with high rates of hospitalization, multisystem involvem...
Read MoreFULL SUPPLEMENT: Emerging Topical Approaches in the Management of Female Pattern Hair Loss
June 2026 | Volume 25 | Issue 6 | Department | 83250s1 | Copyright © June 2026
Alopecia can be categorized as cicatricial and non-cicatricial, with female androgenetic alopecia (AGA) and female pattern hair loss (FPHL) included in the latter category....
Read MoreINDIVIDUAL ARTICLE: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss
June 2026 | Volume 25 | Issue 6 | Supplement Individual Articles | 83251s3 | Copyright © June 2026
Read MoreFULL SUPPLEMENT: Mechanism Matters: IL-17 Receptor Blockade With Brodalumab and Its Role in Durable Psoriasis Clearance and Fast Onset of Action
May 2026 | Volume 25 | Issue 5 | Department | 15470s1 | Copyright © May 2026
Psoriasis is a chronic immune-mediated inflammatory disease driven by dysregulated interleukin-17 (IL-17) signaling across skin and musculoskeletal tissues. While upstream IL-23 inhibition and selecti...
Read MoreINDIVIDUAL ARTICLE: Clinical and Real-World Implications of IL-17 Receptor Blockade in Plaque Psoriasis and Psoriatic Arthritis With Brodalumab
May 2026 | Volume 25 | Issue 5 | Supplement Individual Articles | 15471s3 | Copyright © May 2026
Brodalumab is a fully human monoclonal antibody targeting interleukin-17 receptor A (IL-17RA), providing a mechanistically distinct approach to inhibiting IL-17–mediated inflammation in pla...
Read MoreFULL SUPPLEMENT: 2025 Poster Abstracts Supplement
April 2026 | Volume 25 | Issue 4 | Department | 269616s1 | Copyright © April 2026
Over the past two decades, the Skin of Color Update meeting has been dedicated to delivering continuing medical education to dermatologic audiences that highlights best practices and evolving trends i...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
